Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Aug;26(8):874-884.
doi: 10.1097/GME.0000000000001325.

Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial

Lon S Schneider  1 , Gerson Hernandez  2 , Liqin Zhao  3 , Adrian A Franke  4 , Yu-Ling Chen  1 , Sonia Pawluczyk  1 , Wendy J Mack  1 , Roberta D Brinton  2
Affiliations
Clinical Trial

Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial

Lon S Schneider et al. Menopause. 2019 Aug.

Abstract

Objective: PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-β (ERβ); and may enhance neuron function and estrogenic mechanisms in the brain without having peripheral estrogenic activity.

Methods: We conducted an overarching, two-stage, dose-ranging, double-blinded, randomized, placebo-controlled trial of 12 weeks duration comparing 50 and 100 mg/d of phytoSERM with placebo for noncognitively impaired, perimenopausal women aged 45 to 60, with intact uteri and ovaries, with at least one cognitive complaint, and one vasomotor-related symptom. Primary objectives were to assess safety and tolerability of a 50 and 100 mg daily dose; and, secondly, to evaluate potential indicators of efficacy on cognition and vasomotor symptoms over 4 and 12 weeks, and using an embedded, 4-week, 2-period, placebo-controlled crossover trial for a subset of participants.

Results: Seventy-one women were randomized to treatment; 70 were evaluated at 4 weeks; 12 were entered into the crossover study; 5 did not complete 12 weeks. Reasons for discontinuation were withdrawal of consent (n = 1) and lost to follow-up (n = 4). Adverse events occurred in 16.7% (n = 4) placebo, 39.1% (n = 9) 50 mg/d, and 29.2% (n = 7) 100 mg/d treated participants; 85% were mild and none was severe. Vaginal bleeding occurred in 0, placebo; 1, 50 mg; and 3, 100 mg/d participants.

Conclusions: The phytoSERM formulation was well tolerated at 50 and 100 mg daily doses. Based on safety outcomes, vaginal bleeding at the 100 mg dose, and vasomotor symptoms and cognitive outcomes at 12 weeks, a daily dose of 50 mg was considered preferable for a phase 2 efficacy trial.

Trial registration: ClinicalTrials.gov NCT01723917.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest/ financial disclosures: LSS, GH, AAF, Y-LC, SP, and WJM have no disclosures relevant to this work. RDB and LZ hold US Patents 8552057 and 8680140 on phytoSERM formulation.

Figures

Figure 1.
Figure 1.
CONSORT flow diagram
Figure 2.
Figure 2.
Parallel-group treatment comparisons: Change from baseline on vasomotor and neuropsychological composites, at 4 weeks (A) and 12 weeks (B)
Figure 2.
Figure 2.
Parallel-group treatment comparisons: Change from baseline on vasomotor and neuropsychological composites, at 4 weeks (A) and 12 weeks (B)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351–358. - PubMed
    1. Kantarci K, Tosakulwong N, Lesnick TG, et al. Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology. 2018;90(16):e1404–e1412. - PMC - PubMed
    1. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. Jama. 2003;289(20):2663–2672. - PubMed
    1. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. Journal of Clinical Endocrinology & Metabolism. 2006;91(5):1802–1810. - PubMed
    1. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Consensus Development Conference, NIH Review presented at Ann Intern Med; 2005. - PubMed

Publication types

Associated data